トップランナーが語る　心不全診療のプリンシプル

出版社： 金芳堂
著者：
発行日： 2023-03-20
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784765319423
電子書籍版： 2023-03-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

多様な病態をもつ心不全をどのように診療すればよいか？　トップランナーがそのプリンシプル（原理原則）を本音で語る！　医師・医療従事者に人気のYouTubeチャンネル『心不全・心機能アカデミー』で収録した対談をベースに、心機能・新規治療薬・HFpEF・緩和医療といったホットなトピックを中心に、臨床に活かせる実践的な内容を盛り込みました。心不全診療の最新のトレンドにくわえ、トップランナーの哲学がつかめる最強の一冊。各項目は、ライブ感あふれる対談と重要用語の解説で構成。それぞれYouTubeの対談動画に対応しています（QRコード付き）。

目次

  • 序章　心不全分類の考え方とトレンド　大西勝也

    第1章　心不全治療を理解するための心機能
    1　新規心不全治療薬の心血行動態に及ぼす影響　坂本隆史×大西勝也

    第2章　心不全治療の考え方
    2　心不全治療薬から心不全を考える　佐藤直樹×大西勝也
    3　心不全の標準治療薬をどのように選択するか？　～心不全の診察・治療～　猪又孝元×大西勝也

    第3章　新規心不全治療薬をどう選択するか？
    4　新しい心不全治療薬をすべて投与すべきか？　筒井裕之×大西勝也
    5　心不全におけるナトリウム利尿ペプチドの意義　斎藤能彦×大西勝也
    6　糖尿病併存心不全に対する心不全治療薬・糖尿病薬の考え方　野出孝一×大西勝也
    7　心不全におけるcGMPの役割　室原豊明×大西勝也

    第4章　HFpEFの診断・治療をどう考えるか？
    8　LVEFで心不全を分類すべきか？　瀬尾由広×大西勝也
    9　HFpEFのエコー診断、HFpEFの左室拡張能障害の評価の仕方　土肥薫×大西勝也
    10　HFpEFの問題点　坂田泰史×大西勝也
    11　HFpEFをどう理解するか　山本一博×大西勝也

    第5章　緩和医療
    12　心不全の緩和医療とは？　大石醒悟×大西勝也
    13　緩和ケアの実践　柴田龍宏×大西勝也

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章 心不全分類の考え方とトレンド

P.8 掲載の参考文献
Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 ; 385 : 1451-1461.
PubMed
Fukuta H, Little WC. Contribution of systolic and diastolic abnormalities to heart failure with a normal and a reduced ejection fraction. Prog Cardiovasc Dis. 2007 ; 49 : 229-240.
 
Guyton AC, Hall JE. Textbook of Medical Physiology, 11th ed. Elsevier Saunders. 2006
 
Hall JE. Integration and regulation of cardiovascular function. Am J Physiol. 1999 ; 277 (6 Pt 2) : S174-186.
 
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
Libby P, et al. (eds.) Braunwald's Heart Disease, 12th ed. Elsevier. 2021.
 
大西勝也. 新しい心血行動態入門. メディカ出版. 2014.
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 

第1章 心不全治療を理解するための心機能

P.21 掲載の参考文献
Guyton AC, Hall JE. Textbook of Medical Physiology, 11th ed. Elsevier Saunders. 2006
 
Hubers SA, et al. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016 ; 133 : 1115-1124.
PubMed
Libby P, et al. (eds.) Braunwald's Heart Disease, 12th ed. Elsevier. 2021.
 
大西勝也. 新しい心血行動態入門. メディカ出版. 2014.
 

第2章 心不全治療の考え方

P.38 掲載の参考文献
Butler J, et al. Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction : implications for clinical practice. Eur Heart J. 2020 Sep 21 ; 41 : 3398-3401.
 
Grande D, et al. The effects of heart rate control in chronic heart failure with reduced ejection fraction. Heart Fail Rev. 2018 ; 23 : 527-535.
PubMed
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021 ; 42 : 3599-3726.
 
Pascual-Figal DA, et al. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med. 2021 ; 8 : 754499.
 
Reddy YNV, et al. Novel approaches to the management of chronic systolic heart failure : future directions and unanswered questions. Eur Heart J. 2020 ; 41 : 1764-1774.
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 
P.46 掲載の参考文献
Aimo A, et al. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev. 2022 ; 27 : 1165-1171.
PubMed
Armstrong PW, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator : The VICTORIA Trial. JACC Heart Fail. 2018 ; 6 : 96-104.
PubMed
Grande D, et al. The effects of heart rate control in chronic heart failure with reduced ejection fraction. Heart Fail Rev. 2018 ; 23 : 527-535.
PubMed
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation. 2022 ; 145 : e895-e1032.
 
Libby P, et al. (eds.) Braunwald's Heart Disease, 12th ed. Elsevier. 2021.
 
McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021 ; 42 : 3599-3726.
 
Reddy YNV, et al. Novel approaches to the management of chronic systolic heart failure : future directions and unanswered questions. Eur Heart J. 2020 7 ; 41 : 1764-1774.
 
Rossano GM, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021 ; 23 : 872-881.
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 

第3章 新規心不全治療薬をどう選択するか ?

P.57 掲載の参考文献
Bauersachs J, et al, Heart failure drug treatment : the fantastic four. Eur Heart J. 2021 ; 42 : 681-683.
PubMed
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation. 2022 ; 145 : e895-e1032.
 
McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021 ; 42 : 3599-3726.
 
McMurray JJ, et al. for the PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 ; 371 : 993-1004.
PubMed
McMurray JJV, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 ; 381 : 1995-2008. (Epub 2019 Sep 19.)
 
Packer M, et al. ; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 ; 383 : 1413-1424.
PubMed
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 
P.66 掲載の参考文献
Bauersachs J, et al, Heart failure drug treatment : the fantastic four. Eur Heart J. 2021 ; 42 : 681-683.
PubMed
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation. 2022 ; 145 : e895-e1032.
 
Kuwahara K. The natriuretic peptide system in heart failure : Diagnostic and therapeutic implications. Pharmacol Ther. 2021 ; 227 : 107863.
PubMed
McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 ; 42 : 3599-3726.
 
Nakagawa H, et al. Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases. Biology (Basel). 2022 ; 11 : 1017.
PubMed
Saito Y. Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol. 2010 ; 56 : 262-270.
PubMed
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 
P.74 掲載の参考文献
Baggio LL, et al. Biology of incretins : GLP-1 and GIP. Gastroenterology. 2007 ; 132 : 2131-2157.
PubMed
Dharma A, et al. Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. JACC Heart Fail. 2018 : 6 : 813-822.
 
Harrington WG, et al. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors : a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. Eur Heart J. 2021 ; 23 : 1260-1275.
 
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation. 2022 ; 145 : e895-e1032.
 
McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 ; 42 : 3599-3726.
 
Pernicova I, et al. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014 ; 10 : 143-156.
PubMed
Pop-Busui R, et al. Heart Failure : An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022 ; 45 : 1670-1690.
PubMed
SOLVD Investigators, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 ; 325 : 293-302.
PubMed
Wanner C, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 ; 375 : 323-334.
PubMed
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 
P.81 掲載の参考文献
Armstrong PW, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 ; 382 : 1883-1893.
PubMed
Balligand JL, et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA.1993 ; 90 : 347-351.
PubMed
Cohn JN, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 ; 314 : 1547-1552.
 
Dunkerly-Eyring B, et al. Myocardial Phosphodiesterases and Their Role in cGMP Regulation. J Cardiovasc Pharmacol. 2020 ; 75 : 483-493.
PubMed
Furchgott RF, et al. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 ; 288 : 373-376.
PubMed
Lefer AM, et al. Comparative pharmacology of nitric oxide and nitric oxide generators on cardiac contractility in mammalian species. Int J Cardiol. 1995 ; 50 : 239-242.
PubMed
Murohara T, et al. Interactions of nitrovasodilators, atrial natriuretic peptide and endotheliumderived nitric oxide. J Vasc Res. 1996 ; 33 : 78-85.
PubMed
Palmer RM, et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 ; 327 : 524-526.
PubMed
Weyrich AS, et al. Physiological concentrations of nitric oxide do not elicit an acute negative inotropic effect in unstimulated cardiac muscle. Circ Res. 1994 ; 75 : 692-700.
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 

第4章 HFpEF の診断・治療をどう考えるか ?

P.91 掲載の参考文献
Galderisi M, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations : an expert consensus document of the European Association of Cardiovascular ImagingEur Heart J Cardiovasc Imaging. 2017 ; 18 : 1301-1310.
 
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
Libby P, et al. (eds.) Braunwald's Heart Disease, 12th ed. Elsevier. 2021.
 
Oh JK, et al. The Echo Manual, 3rd ed. Lippincott Williams & Wilkins. 2006.
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 
P.100 掲載の参考文献
Oh JK, et al. The Echo Manual, 3rd ed. Lippincott Williams & Wilkins. 2006.
 
Pieske B. How to diagnose heart failure with preserved ejection fraction : the HFA-PEFF diagnostic algorithm : a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 ; 40 ; 3297-3317.
 
Reddy YNV, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018 ; 138 : 861-870.
PubMed
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 
P.115 掲載の参考文献
Abbate A, et al. Heart failure with preserved ejection fraction : refocusing on diastole. Int J Cardiol. 2015 ; 179 : 430-440.
PubMed
Borlaug BA, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010 ; 3 : 588-595.
PubMed
Fallick C, et al. Sympathetically mediated changes in capacitance : redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail. 2011 ; 4 : 669-675.
PubMed
Fudim M, et al. Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction : First-in-Human Study. JACC Heart Fail. 2022 ; 10 : 744-752.
PubMed
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
Iwano H, et al. Heart failure : what does ejection fraction have to do with it? J Cardiol. 2013 ; 62 : 1-3.
 
Michra S, et al. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021 ; 18 : 400-423.
 
Oh JK, et al. The Echo Manual, 3rd ed. Lippincott Williams & Wilkins. 2006.
 
Reddy YNV, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018 ; 138 : 861-870.
PubMed
加藤真帆人. エキスパートが現場で明かす心不全診療の極意. 南山堂. 2016.
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 
P.128 掲載の参考文献
Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 ; 385 : 1451-1461.
PubMed
Borlaug BA, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006 ; 114 : 2138-2147.
 
Libby P, et al. (eds.) Braunwald's Heart Disease, 12th ed. Elsevier. 2021.
 
McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 ; 381 : 1995-2008.
PubMed
Pitt B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 ; 370 : 1383-1392.
PubMed
The PARAGON investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation. 1998 ; 97 : 2386-2395.
PubMed
Yamamoto K, et al. Effects of carvedilol on heart failure with preserved ejection fraction : the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013 ; 15 : 110-118.
PubMed
山本一博. 心臓の機能と力学. 文光堂. 2014.
 
大西勝也. 新しい心血行動態入門. メディカ出版. 2014.
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデー版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 

第5章 緩和医療

P.137 掲載の参考文献
Ariadne Labs. Serious Illness Care. https://www.ariadnelabs.org/areas-of-work/serious-illness-care/
 
Butler J, et al. Advance directives among hospitalized patients with heart failure. JACC Heart Fail. 2015 ; 3 : 112-121.
PubMed
Respecting Choices(R). https://respectingchoices.org/
 
厚生労働省. 緩和ケア診療加算 (A226-2). https://kouseikyoku.mhlw.go.jp/chugokushikoku/news/2012/tazaitoyo/000194787.pdf
 
厚生労働省. 人生の最終段階における医療・ケアの決定プロセスに関するガイドライン. 2018年3月改訂. https://www.mhlw.go.jp/file/04-Houdouhappyou-10802000-Iseikyoku-Shidouka/0000197701.pdf
 
日本循環器学会/日本心不全学会. 2021年改訂版循環器疾患における緩和ケアについての提言. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Anzai.pdf (2022年12月閲覧)
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 
P.150 掲載の参考文献
Chua TP, et al. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 1997 ; 29 : 147-152.
PubMed
Gillick MR. Advance care planning. N Engl J Med. 2004 ; 350 : 7-8.
PubMed
Shibata T, et al. Evaluation of the effectiveness of the physician education program on primary palliative care in heart failure. PLoS One. 2022 ; 17 : e0263523.
PubMed
Sobanski PZ, et al. Palliative care for people living with heart failure : European Association for Palliative Care Task Force expert position statement. Cardiovasc Res. 2020 ; 116 : 12-27.
PubMed
Williams SG, et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart. 2003 ; 89 : 1085-1086.
PubMed
日本循環器学会/日本心不全学会. 2021年改訂版 循環器疾患における緩和ケアについての提言. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Anzai.pdf (2022年12月閲覧)
 
日本循環器学会/日本心不全学会. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年12月閲覧)
 

書評

最近チェックした商品履歴

Loading...